Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, includ…
Biotechnology
US, Plano [HQ]
RETA/Financial Reporting
Income Statements
10 Sheets · Starting from 2022In Million USD. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.00 | 51.00 | 50.00 | 49.00 | 48.00 | 53.00 | 26.00 | 9.00 | 11.00 | 2.00 | |
|
EPS
|
-6.38 | 0.13 | -0.26 | -0.31 | -1.99 | -2.91 | -9.54 | -7.35 | -8.19 | -8.59 | |
| Diluted in mil. | -1.76 | 0.03 | -0.26 | -0.31 | -1.99 | -2.91 | -9.54 | -7.35 | -8.19 | -8.59 | |
|
Profit
|
51.00 | 51.00 | 50.00 | 49.00 | 48.00 | 53.00 | -97.00 | 9.00 | 11.00 | 2.00 | |
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | -369.13 | 100.00 | 100.00 | 100.00 | |
| Pre Tax | -10.00 | 3.00 | - - | -6.00 | -47.00 | -80.00 | -290.00 | -270.00 | -297.00 | -311.00 | |
| Profit Margin | -20.21 | 7.06 | -0.60 | -13.37 | -99.19 | -150.25 | -1,094.25 | -2,996.33 | -2,592.13 | -14,076.08 | |
| ETR | -239.31 | 81.22 | -380.13 | 6.61 | -0.01 | -0.03 | - - | 8.32 | 0.15 | 0.01 | |
| Net | -35.00 | - - | -1.00 | -6.00 | -47.00 | -80.00 | -290.00 | -247.00 | -297.00 | -311.00 | |
| Profit Margin | -68.56 | 1.33 | -2.88 | -12.49 | -99.19 | -150.30 | -1,094.28 | -2,747.00 | -2,588.22 | -14,074.95 | |
| EBITDA | -7.00 | 6.00 | 1.00 | -6.00 | -46.00 | -76.00 | -284.00 | -225.00 | -243.00 | -269.00 | |
| EBITDA Margin | -14.63 | 11.73 | 2.89 | -12.87 | -96.71 | -142.65 | -1,072.10 | -2,496.83 | -2,119.28 | -12,140.12 | |
| Operating Income | -10.00 | 3.00 | - - | -7.00 | -46.00 | -76.00 | -285.00 | -226.00 | -244.00 | -270.00 | |
| Operating Margin | -20.35 | 6.89 | -0.73 | -14.23 | -97.62 | -143.46 | -1,075.61 | -2,509.42 | -2,129.75 | -12,191.11 | |
| Interest Income | - - | - - | - - | - - | - - | - - | - - | - - | - - | 5.00 | |
| Loss | -61.00 | -48.00 | -50.00 | -56.00 | -94.00 | -130.00 | -311.00 | -235.00 | -256.00 | -280.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | -124.00 | - - | - - | - - | |
|
Operating Expenses
|
-61.00 | -48.00 | -50.00 | -56.00 | -94.00 | -130.00 | -187.00 | -235.00 | -256.00 | -280.00 | |
| R&D | -45.00 | -34.00 | -35.00 | -39.00 | -71.00 | -97.00 | -128.00 | -159.00 | -155.00 | -169.00 | |
| G&A | -13.00 | -11.00 | -13.00 | -16.00 | -23.00 | -32.00 | -58.00 | -75.00 | -99.00 | -109.00 | |
| SG&A | -13.00 | -11.00 | -13.00 | -16.00 | -23.00 | -32.00 | -58.00 | -75.00 | -99.00 | -109.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Depreciation and Amortization | -2.00 | -2.00 | -1.00 | - - | - - | - - | - - | -1.00 | -1.00 | -1.00 | |
| Interest Expenses | - - | - - | - - | - - | -1.00 | -6.00 | -11.00 | -36.00 | -53.00 | -41.00 | |
| Other Expenses | - - | - - | - - | - - | - - | -2.00 | -4.00 | -43.00 | -53.00 | -41.00 | |
|
WA Shares Outstanding
|
5.00 | 5.00 | 5.00 | 19.00 | 23.00 | 27.00 | 30.00 | 33.00 | 36.00 | 36.00 | |
| Diluted | 19.00 | 19.00 | 5.00 | 19.00 | 23.00 | 27.00 | 30.00 | 33.00 | 36.00 | 36.00 |